The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HER2 and HER3 expression in ovarian cancer: Evolution across chemotherapy exposure and implications for targeted therapies.
 
Felix Blanc-Durand
Honoraria - Cureety
Consulting or Advisory Role - AstraZeneca/Merck (Inst); Eisai/MSD; GlaxoSmithKline (Inst)
Research Funding - AstraZeneca/MedImmune (Inst); Daiichi Sankyo Europe GmbH (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; GlaxoSmithKline
 
Audrey Le Formal
No Relationships to Disclose
 
Elisa Yaniz
No Relationships to Disclose
 
Kaïssa Ouali
Consulting or Advisory Role - Amgen; Anaveon; Sotio
Travel, Accommodations, Expenses - Amgen; Eisai; Sotio
 
Catherine Genestie
No Relationships to Disclose
 
Alexandra Leary
Honoraria - Gerson Lehrman Group; Medscape; peervoice
Consulting or Advisory Role - Abbvie (Inst); Apmonia Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Merck Serono (Inst); MSD (Inst); PEGASCY; Pharmend (Inst); Seagen (Inst); Tesaro (Inst); zentalis (Inst)
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Inivata (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); owkin (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Oseimmuno; Tesaro